Opendata, web and dolomites

Light4Sight SIGNED

Light-activated carriers for the controlled delivery of therapeutic peptides in posterior segment eye diseases

Total Cost €


EC-Contrib. €






 Light4Sight project word cloud

Explore the words cloud of the Light4Sight project. It provides you a very rough idea of what is the project "Light4Sight" about.

35    injected    nanocarriers    treatment    protein    provides    posterior    moderate    minimizes    degeneration    billion    reduces    sensitive    light    supramolecular    drug    peptide    systemic    irradiation    consisting    match    site    exceeded    burden    invasive    glaucoma    visible    topical    incorporating    lifestyle    rapid    biopharmaceuticals    doses    vitreoretinal    therapeutic    half    adverse    patients    light4sight    demand    2025    intraocular    suffering    sales    ocular    ing    market    barriers    life    treatments    assembling    repeated    risk    hydrogel    suspended    evades    protects    ophthalmic    acceptable    self    drugs    injections    providers    global    healthcare    quality    vision    age    release    innovative    vitreous    patient    avoiding    administration    treat    benefits    clearance    diseases    peptides    population    burst    concentration       eye    dose    therapy    platform    primarily    loading    frequent    2016    biopharmaceutical    placing    reducing    injection    aged    complete    alternative    activated    consequently    retinopathy    pose    diabetic    macular    ways    chronic    intravitreal    toxicity   

Project "Light4Sight" data sheet

The following table provides information about the project.


Organization address
address: 327 MILE END ROAD
city: LONDON
postcode: E1 4NS

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 224˙933 €
 EC max contribution 224˙933 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2021-10-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    QUEEN MARY UNIVERSITY OF LONDON UK (LONDON) coordinator 224˙933.00


 Project objective

In 2016, the global sales of biopharmaceutical drugs (protein, peptides) in ophthalmic applications exceeded $8 billion and is estimated to increase to $35.7 billion by 2025. The growth of the ophthalmic drug market is primarily driven by an increasing aged population suffering from age- and lifestyle-related diseases such as macular degeneration, diabetic retinopathy, glaucoma, among others. These diseases cause moderate or complete vision loss, resulting in significant reduction in quality of life. Consequently, innovative approaches for the effective delivery of biopharmaceuticals for the treatment of chronic intraocular diseases are required. Currently, intravitreal injection of drugs is the most acceptable and effective method to treat vitreoretinal diseases. By placing the drug in the posterior eye, it evades the ocular barriers common in topical and systemic delivery, allowing higher drug doses to reach the target site. However, treatments require frequent injections to maintain adequate intraocular concentration, which are invasive, increase the risk of adverse effects and pose significant treatment burden on patients and healthcare providers. Thus, alternative ways to deliver these drugs that require less frequent administration need to be developed. Light4Sight aims to develop a novel delivery platform consisting of self-assembling nanocarriers incorporating therapeutic peptides and suspended within a light-sensitive supramolecular hydrogel. The hydrogel can be injected in the vitreous and release of nanocarriers be activated through the irradiation of visible light. This approach provides several benefits: 1) minimizes the use of repeated injections reducing treatment burden; 2) reduces burst release of the nanocarriers avoiding potential dose related toxicity; 3) on-demand release to match patient needs; 4) allows high drug loading for long-term therapy; 5) protects peptide drugs from rapid clearance in the vitreous increasing their half-life.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIGHT4SIGHT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LIGHT4SIGHT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MIGPSC (2018)

Shaping the European Migration Policy: the role of the security industry

Read More  

lanloss (2020)

Landscapes of Loss: Mapping the Affective Experience of Deforestation Among Diverse Social Groups in the South American Chaco

Read More  

DEMOS (2019)

Disfluencies and Eye MOvements during Speech: what can they reveal about language production?

Read More